OnKure Therapeutics, Inc. Cash Flow Statement
OKUR|1 years of annual SEC 10-K data (FY2024-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
OnKure Therapeutics, Inc. used $35M in operating cash flow and negative free cash flow of $35M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.56 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 |
|---|---|
| Net Income | -$35.3M |
| Depreciation & Amortization | $417.0K |
| Operating Cash Flow | -$34.5M |
| Capital Expenditures | $246.0K |
| Free Cash Flow | -$34.8M |